



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

July 15, 2020

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Disclosure of related party transactions for the half year ended March 31, 2020

Ref.: 1. Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
2. Scrip Code: 500672

Dear Sir/ Madam,

Apropos the subject matter quoted above, please find enclosed herewith the disclosure of Related Party Transactions on a standalone basis, in format as specified in the relevant accounting standards for the half year ended March 31, 2020.

The above is for your information and the same is also available on the Company's website i.e. www.novartis.in

Thanking you

Yours sincerely,

For **Novartis India Limited**

Sd/-
Trivikram Guda
Company Secretary &
Compliance Officer

Novartis India Limited
Related Party Disclosures for the period - Half year ended on March 31, 2020

(A) Enterprise where control exists

Holding Company and Ultimate Holding Company Novartis AG, Basel, Switzerland

(B) Other Related Parties with whom the company had transactions during the year and/or the previous year

(i) Fellow Subsidiaries

Novartis Healthcare Private Limited, India
 Novartis Holding AG, Switzerland
 Novartis Asia Pacific Pharmaceuticals Pte Ltd
 Novartis Pharma AG, Switzerland
 Novartis Pharma Services INC Kenya
 Sandoz Private Limited, India
 Novartis Institutes for Biomedical Research Co. Ltd

(ii) List of other related parties (Post-employment benefit plan of Novartis India Limited)

Novartis India Limited Employees' Provident Fund
 Novartis India Limited Superannuation Fund

(C) Key Management Personnel

Mr. Sanjay Murdeshwar - Managing Director
 Mr. Felix Doss - Chief Financial Officer
 Mr. Trivikram Guda - Company Secretary & Compliance Officer

 Mr. Christopher Snook - Non-Executive Director (Chairman)
 Mr. Jai Hiremath - Independent Director
 Ms. Sandra Martyes - Independent Director
 Dr. Rajendra Nath Mehrotra - Independent Director (upto March 31, 2020)
 Ms. Monaz Noble - Non-Executive & Non-Independent Director

(D) Disclosure of transactions between the company and related parties and outstanding balances as at the half year end:

Half year ended 31 Mar 2020
in ₹ million

(a) Holding Company and Ultimate Holding Company

Dividend paid	-
Royalty Expense	17.2
Balance as at the year end - Outstanding Payable	101.4

(b) Fellow Subsidiaries

Purchases of Stock-in-Trade Novartis Pharma AG	135.5
	135.5
Sale of Services	
Novartis Healthcare Private Limited	10.3
Novartis Pharma AG	7.8
Sandoz Private Limited	14.8
Novartis Asia Pacific Pharmaceutical Pte Limited	0.7
Novartis Pharma Services INC Kenya	17.2
Novartis Institutes for Biomedical Research Co. Ltd	0.3
	51.1
Commission Income	
Novartis Healthcare Private Limited	124.0
Services Availed	
Novartis Healthcare Private Limited	26.9
Novartis Pharma AG	1.1
	28.0

	Half year ended 31 Mar 2020 in ₹ million
Purchase of Restricted Shares of Novartis AG on behalf of employees of the Company by Novartis Holding AG	24.1
	<u>24.1</u>
Expenses paid by related party on behalf of the Company Novartis Healthcare Private Limited Sandoz Private Limited	2.3
	0.5
	<u>2.8</u>
Expenses paid by the Company on behalf of the related party Sandoz Private Limited Novartis Asia Pacific Pharmaceuticals Pte Ltd	1.1
	0.6
	<u>1.712</u>

	Half year ended 31 Mar 2020 in ₹ million
Balances as at the half year end - Outstanding Receivables Novartis Healthcare Private Limited Novartis Pharma AG Novartis Holding AG Sandoz Private Limited Novartis Pharma Services INC Kenya Novartis Institutes for Biomedical Research Co. Ltd	112.1
	317.7
	-
	9.4
	7.1
	0.3
	<u>446.6</u>

	Half year ended 31 Mar 2020 in ₹ million
Outstanding Payables Novartis Healthcare Private Limited Novartis Holding AG Novartis Asia Pacific Pharmaceuticals Pte Ltd Novartis Pharma AG Sandoz Private Limited	956.3
	26.3
	0.6
	154.1
	8.5
	<u>1,145.8</u>

(c) Post Employment Benefit Plans of Novartis India Limited

	Half year ended 31 Mar 2020 in ₹ million
Contribution to In-house Trust for Post Employment Benefits Novartis India Limited Employees' Provident Fund Novartis India Limited Superannuation Fund	(19.1)
	0.3
	<u>(18.8)</u>

(d) Key Management Personnel Compensation

	Half year ended 31 Mar 2020 in ₹ million
Short-term employee benefits	1.8
Post-employment benefits	(0.5)
Other long-term benefits	0.8
Commission to Independent Directors*	3.0
Sitting fees to Independent Directors	0.6
Total compensation	<u>5.8</u>

* Actual amount for the entire FY 19-20 would be paid post adoption of Financial Statements by the Shareholders.

Notes:

1) No amounts have been written off/provided for or written back in respect of amounts receivable from or payable to the related parties.

2) Outstanding balances at the half year-end are unsecured and interest free and settlement occurs in cash.